Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 7

Noninvasive mechanical ventilation with BiPAP therapy for comatose exacerbation of chronic obstructive pulmonary disease through an endotracheal tube: is it justified?

Authors Esquinas A, Agarwal R

Received 15 September 2012

Accepted for publication 28 October 2012

Published 3 December 2012 Volume 2012:7 Pages 807—809


Checked for plagiarism Yes

Antonio Esquinas,1 Ritesh Agarwal2

Intensive Care Unit, Hospital Morales Meseguer, Murcia, Spain; 2Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

We read with interest the paper by Rawat et al1 related to the role of bilevel positive airway pressure (BiPAP) delivered via endotracheal tube in unconscious patients suffering from acute exacerbations of chronic obstructive pulmonary disease in a real-world situation. Although the authors provide some justification for the use of BiPAP through an endotracheal tube, we believe that this technique is fraught with complications and should not be routinely employed. In fact, three patients failed BiPAP therapy, two patients received conventional invasive ventilation, and one patient failed to respond to BiPAP. Thus, almost 30% of patients either failed or showed no evidence for benefit of BiPAP. Further, the authors provide no data on the amount of leakage that was present while administering BiPAP therapy. The authors also do not provide details on whether the nurses/chest therapist administered intermittent manual bag ventilation. Ideally, the authors should have referred the patients on manual bag ventilation to another public health center where facilities for invasive ventilation are available free of cost.

View original paper by Rawat and colleagues.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Readers of this article also read:

Cytotoxicity and physicochemical characterization of iron–manganese-doped sulfated zirconia nanoparticles [Corrigendum]

Al-Fahdawi MQ, Rasedee A, Al-Qubaisi MS, Alhassan FH, Rosli R, El Zowalaty ME, Naadja SE, Webster TJ, Taufiq-Yap YH

International Journal of Nanomedicine 2015, 10:6657-6658

Published Date: 28 October 2015

Methotrexate-loaded lipid-core nanocapsules are highly effective in the control of inflammation in synovial cells and a chronic arthritis model

Boechat AL, Oliveira CP, Tarragô AM, Costa AG, Malheiro A, Guterres SS, Pohlmann AR

International Journal of Nanomedicine 2015, 10:6603-6614

Published Date: 22 October 2015

Molecular targets in arthritis and recent trends in nanotherapy

Roy K, Kanwar RK, Kanwar JR

International Journal of Nanomedicine 2015, 10:5407-5420

Published Date: 26 August 2015

Chloramphenicol encapsulated in poly-ε-caprolactone–pluronic composite: nanoparticles for treatment of MRSA-infected burn wounds

Kalita S, Devi B, Kandimalla R, Sharma KK, Sharma A, Kalita K, Kataki AC, Kotoky J

International Journal of Nanomedicine 2015, 10:2971-2984

Published Date: 15 April 2015

Electrospun gelatin/polycaprolactone nanofibrous membranes combined with a coculture of bone marrow stromal cells and chondrocytes for cartilage engineering

He X, Feng B, Huang C, Wang H, Ge Y, Hu R, Yin M, Xu Z, Wang W, Fu W, Zheng J

International Journal of Nanomedicine 2015, 10:2089-2099

Published Date: 17 March 2015

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010

Infliximab in the treatment of rheumatoid arthritis

A Perdriger

Biologics: Targets and Therapy 2009, 3:183-191

Published Date: 7 May 2009